Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Pharmaceuticals Inc.

www.vrtx.com

Latest From Handok Pharmaceuticals Co. Ltd.

Pipeline Watch: Phase III Starts With Filgotinib, Gilteritinib And Nivolumab

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical Trials

Genexine Seeks China Entry Through Multi-Biologic Tasly Tie-Up

South Korean biotech firm Genexine is broadening its presence in Asia. Following an agreement earlier this month with Kalbe Farma to set up a joint venture in Indonesia, it has now signed a licensing out deal for protein therapies with a subsidiary of China’s Tasly Pharmaceutical.

BioPharmaceutical China

Korean Pharma Seen Pursuing Three Main M&A Types

Although mergers and acquisitions among South Korean pharma and healthcare firms haven't been relatively active or great in value, smaller scale acquisitions or share investments have continuously taken place in recent years. These can be broken down into three major types with their own benefits and such trends are likely to continue, predicts a new analysis.

BioPharmaceutical South Korea

Korea’s Celltrion Dismisses As Rumor Reports That AstraZeneca, Roche And Teva Are Interested Buyers

Celltrion reveals little about the progress of Chairman Seo Jung-jin’s share sell-off as the company’s clinical development moves forward on a Rituxan biosimilar.

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vertex Pharmaceuticals Inc.
  • Senior Management
  • Jeffrey Leiden, MD, PhD, Chmn., Pres. & CEO
    Ian F Smith, EVP, CFO & COO
    Stuart A Arbuckle, EVP, Chief Commercial Officer
    David Altshuler, MD, PhD, EVP, Global Research & CSO
  • Contact Info
  • Vertex Pharmaceuticals Inc.
    Phone: (617) 444-6100
    50 Northern Ave.
    Boston, MA 02210
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register